Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oppenheimer initiated coverage on Vaxart Inc. (NASDAQ:VXRT), an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
Oppenheimer對美國生物技術公司Vaxart Inc.（NASDAQ：VXRT）進行了覆蓋，並專注於口服重組疫苗的發現、開發和商業化等關鍵方面。
The analyst's bullish view is centered around optimism associated with attractive opportunities for Vaxart's 'differentiated' oral vaccine platform and key programs, such as the norovirus vaccine and COVID-19 vaccine.
分析師的看好觀點集中於看好Vaxart「不同尋常」的口服疫苗平台和重點項目，如諾如病毒疫苗和COVID-19疫苗的樂觀前景。
Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside.
Oppenheimer以業績卓越的評級和4美元的目標價格開局，代表了顯着的潛在上漲空間。
"VXRT is uniquely positioned as a leading company developing oral vaccines against COVID-19, supported by one of the largest BARDA-funded Project NextGen Awards," the analyst writes.
分析師寫道：「VXRt作爲一家領先的口服疫苗開發公司，正在開發針對COVID-19的口服疫苗之一，並得到了最大的BARDA資助之一。」
"We think oral vaccines hold unique properties that may complement intramuscular vaccines to fulfill global healthcare promise," the analyst adds.
分析師補充道：「我們認爲，口服疫苗具有獨特的特性，可以補充肌肉注射疫苗，以實現全球衛生保障的承諾。」
Also Read: Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering.
還閱讀：Vaxart獲得價值4530萬美元的BARDA資助，尋求通過股份發行籌集4000萬美元。
Although norovirus poses significant global health and economic challenges, there is currently no approved vaccine.
儘管諾如病毒引發了重大的全球健康和經濟挑戰，但目前尚無批准的疫苗。
With an estimated market potential of $5 billion-10 billion due to the unmet need, a norovirus vaccine could follow a path similar to RSV vaccines that have gained ACIP recommendations.
由於市場需求未得到滿足，諾如病毒疫苗的預計市場潛力爲50億-100億美元，可能會追隨獲得ACIP建議的RSV疫苗的路徑。
Vaxart is developing a VP-1-based bivalent oral vaccine for norovirus. Oppenheimer sees strong potential in this area, citing the lack of approved vaccines despite the virus's significant health and economic impact.
Vaxart正在爲諾如病毒開發基於VP-1的二價口服疫苗。Oppenheimer認爲該領域具有很強的潛力，並引用了目前儘管諾如病毒的健康和經濟影響巨大，但尚無批准疫苗的事實。
The analyst suggests that Vaxart's oral tablet could offer better immunity than traditional intramuscular vaccines, which have faced challenges. They also view Vaxart as a leader in norovirus vaccine development, positioning it for potential commercial success.
分析師建議，Vaxart的口服藥片可能比傳統的肌肉注射疫苗提供更好的免疫力，而這些注射疫苗面臨着諸多挑戰。他們還認爲Vaxart在諾如病毒疫苗的開發領域是領先者，有望取得商業上的成功。
Price Action: VXRT stock is up 21% at $0.715 at the last check on Thursday.
股票最後一次檢查時，VXRt股票上漲了21％，達到0.715美元。
- Meta Shuts Down Tracking Tool CrowdTangle, Faces Bipartisan Criticism.
- Meta關閉了CrowdTangle跟蹤工具，面臨兩黨的批評。
Don't miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you're a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
不要錯過機會，在10月9-10日的Benzinga SmallCAP會議上主導波動市場。獲得CEO演示文稿的獨家訪問，與投資者進行1：1會議，並獲得來自頂尖金融專家的寶貴見解。無論您是交易員、企業家還是投資者，此活動都提供了無與倫比的機會，使您的投資組合得到增長，並與行業領袖建立聯繫。現在就立即預訂您的位置併購買門票吧！
譯文內容由第三人軟體翻譯。